Search

Your search keyword '"Baron, Ari D."' showing total 9 results
Start Over Author "Baron, Ari D." Publisher elsevier bv
9 results on '"Baron, Ari D."'

2. A phase 1b study of lenvatinib plus pembrolizumab in unresectable hepatocellular carcinoma

Author

Finn, Richard, primary, Ikeda, Masafumi, additional, Zhu, Andrew, additional, Sung, Max W., additional, Baron, Ari D., additional, Kudo, Masatoshi, additional, Okusaka, Takuji, additional, Kobayashi, Masahiro, additional, Kumada, Hiromitsu, additional, Kaneko, Shuichi, additional, Pracht, Marc, additional, Mamontov, Konstantin, additional, Meyer, Tim, additional, Mody, Kalgi, additional, Kubota, Tomoki, additional, Dutcus, Corina E., additional, Saito, Kenichi, additional, Siegel, Abby B., additional, Dubrovsky, Leonid, additional, and Llovet, Josep M., additional

Published
2020
Full Text
View/download PDF

3. Randomised phase II trial (SWOG S1310) of single agent MEK inhibitor trametinib Versus 5-fluorouracil or capecitabine in refractory advanced biliary cancer

Author

Kim, Richard D., primary, McDonough, Shannon, additional, El-Khoueiry, Anthony B., additional, Bekaii-Saab, Tanios S., additional, Stein, Stacey M., additional, Sahai, Vaibhav, additional, Keogh, George P., additional, Kim, Edward J., additional, Baron, Ari D., additional, Siegel, Abby B., additional, Barzi, Afsaneh, additional, Guthrie, Katherine A., additional, Javle, Milind, additional, and Hochster, Howard, additional

Published
2020
Full Text
View/download PDF

4. Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: a subgroup analysis of the phase 3 CELESTIAL trial

Author

Kelley, RobinKate, primary, Ryoo, Baek-Yeol, additional, Merle, Philippe., additional, Park, Joong-Won, additional, Bolondi, Luigi, additional, Chan, Stephen L., additional, Lim, HoYeong, additional, Baron, Ari D., additional, Parnis, Francis, additional, Knox, Jennifer, additional, Cattan, Stéphane, additional, Yau, Thomas, additional, Lougheed, Julie C., additional, Milwee, Steven, additional, El-Khoueiry, Anthony B., additional, Cheng, Ann-Lii, additional, Meyer, Tim, additional, and Abou-Alfa, Ghassan K., additional

Published
2020
Full Text
View/download PDF

5. Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial

Author

Dufour, Jean-François, Schwartz, Jonathan D, Zhu, Andrew X, Pastorelli, Davide, Chau, Ian, REACH Trial, Investigators., Chang, Shao-Chun, Okusaka, Takuji, Ryoo, Baek-Yeol, Chung, Hyun Cheol, Blanc, Jean-Frederic, Trojan, Jorg, Sastre, Javier, Kubackova, Katerina, Abada, Paolo B, Yen, Chia-Jui, Yang, Ling, Pfiffer, Tulio Eduardo Flesch, Kudo, Masatoshi, Baron, Ari D, Poon, Ronnie, Park, Joon Oh, Zhu AX, Park JO, Ryoo BY, Yen CJ, Poon R, Pastorelli D, Blanc JF, Chung HC, Baron AD, Pfiffer TE, Okusaka T, Kubackova K, Trojan J, Sastre J, Chau I, Chang SC, Abada PB, Yang L, Schwartz JD, Kudo M, REACH Trial Investigator, Brandi G., Zhu A.X., Park J.O., Ryoo B.-Y., Yen C.-J., Poon R., Pastorelli D., Blanc J.-F., Chung H.C., Baron A.D., Pfiffer T.E.F., Okusaka T., Kubackova K., Trojan J., Sastre J., Chau I., Chang S.-C., Abada P.B., Yang L., Schwartz J.D., Kudo M., and Craxì Antonio.

Subjects
Male, Time Factors, Kaplan-Meier Estimate, Gastroenterology, Liver disease, Clinical endpoint, 610 Medicine & health, ramucirumab, sorafenib, HCC, Aged, 80 and over, education.field_of_study, Liver Neoplasms, Remission Induction, Antibodies, Monoclonal, Middle Aged, Sorafenib, Treatment Outcome, Oncology, Liver Neoplasm, Hepatocellular carcinoma, Female, Survival Analysi, Human, medicine.drug, Adult, Niacinamide, Phenylurea Compound, medicine.medical_specialty, Carcinoma, Hepatocellular, Time Factor, Population, Antibodies, Monoclonal, Humanized, Placebo, Disease-Free Survival, Drug Administration Schedule, Follow-Up Studie, Ramucirumab, Double-Blind Method, Internal medicine, Confidence Intervals, medicine, Carcinoma, Humans, education, Proportional Hazards Models, Aged, Dose-Response Relationship, Drug, business.industry, Phenylurea Compounds, Patient Selection, medicine.disease, Survival Analysis, digestive system diseases, Surgery, Proportional Hazards Model, business, Confidence Interval, Follow-Up Studies
Abstract

Background: VEGF and VEGF receptor-2-mediated angiogenesis contribute to hepatocellular carcinoma pathogenesis. Ramucirumab is a recombinant IgG1 monoclonal antibody and VEGF receptor-2 antagonist. We aimed to assess the safety and efficacy of ramucirumab in advanced hepatocellular carcinoma following first-line therapy with sorafenib. Methods: In this randomised, placebo-controlled, double-blind, multicentre, phase 3 trial (REACH), patients were enrolled from 154 centres in 27 countries. Eligible patients were aged 18 years or older, had hepatocellular carcinoma with Barcelona Clinic Liver Cancer stage C disease or stage B disease that was refractory or not amenable to locoregional therapy, had Child-Pugh A liver disease, an Eastern Cooperative Oncology Group performance status of 0 or 1, had previously received sorafenib (stopped because of progression or intolerance), and had adequate haematological and biochemical parameters. Patients were randomly assigned (1:1) to receive intravenous ramucirumab (8 mg/kg) or placebo every 2 weeks, plus best supportive care, until disease progression, unacceptable toxicity, or death. Randomisation was stratified by geographic region and cause of liver disease with a stratified permuted block method. Patients, medical staff, investigators, and the funder were masked to treatment assignment. The primary endpoint was overall survival in the intention-to-treat population. This study is registered with ClinicalTrials.gov, number NCT01140347. Findings: Between Nov 4, 2010, and April 18, 2013, 565 patients were enrolled, of whom 283 were assigned to ramucirumab and 282 were assigned to placebo. Median overall survival for the ramucirumab group was 9·2 months (95% CI 8·0-10·6) versus 7·6 months (6·0-9·3) for the placebo group (HR 0·87 [95% CI 0·72-1·05]; p=0·14). Grade 3 or greater adverse events occurring in 5% or more of patients in either treatment group were ascites (13 [5%] of 277 patients treated with ramucirumab vs 11 [4%] of 276 patients treated with placebo), hypertension (34 [12%] vs ten [4%]), asthenia (14 [5%] vs five [2%]), malignant neoplasm progression (18 [6%] vs 11 [4%]), increased aspartate aminotransferase concentration (15 [5%] vs 23 [8%]), thrombocytopenia (13 [5%] vs one [

Published
2015

6. Corrigendum to ‘Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study’ [Eur J Canc 81 (2017) 17–25]

Author

Chau, Ian, primary, Peck-Radosavljevic, Markus, additional, Borg, Christophe, additional, Malfertheiner, Peter, additional, Seitz, Jean Francois, additional, Park, Joon Oh, additional, Ryoo, Baek-Yeol, additional, Yen, Chia-Jui, additional, Kudo, Masatoshi, additional, Poon, Ronnie, additional, Pastorelli, Davide, additional, Blanc, Jean-Frederic, additional, Chung, Hyun Cheol, additional, Baron, Ari D., additional, Okusaka, Takuji, additional, Bowman, L., additional, Cui, Zhanglin Lin, additional, Girvan, Allicia C., additional, Abada, Paolo B., additional, Yang, Ling, additional, and Zhu, Andrew X., additional

Published
2018
Full Text
View/download PDF

7. Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study

Author

Chau, Ian, primary, Peck-Radosavljevic, Markus, additional, Borg, Christophe, additional, Malfertheiner, Peter, additional, Seitz, Jean Francois, additional, Park, Joon Oh, additional, Ryoo, Baek-Yeol, additional, Yen, Chia-Jui, additional, Kudo, Masatoshi, additional, Poon, Ronnie, additional, Pastorelli, Davide, additional, Blanc, Jean-Frederic, additional, Chung, Hyun Cheol, additional, Baron, Ari D., additional, Okusaka, Takuji, additional, Bowman, L., additional, Cui, Zhanglin Lin, additional, Girvan, Allicia C., additional, Abada, Paolo B., additional, Yang, Ling, additional, and Zhu, Andrew X., additional

Published
2017
Full Text
View/download PDF

8. Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial

Author

Zhu, Andrew X, primary, Park, Joon Oh, additional, Ryoo, Baek-Yeol, additional, Yen, Chia-Jui, additional, Poon, Ronnie, additional, Pastorelli, Davide, additional, Blanc, Jean-Frederic, additional, Chung, Hyun Cheol, additional, Baron, Ari D, additional, Pfiffer, Tulio Eduardo Flesch, additional, Okusaka, Takuji, additional, Kubackova, Katerina, additional, Trojan, Jorg, additional, Sastre, Javier, additional, Chau, Ian, additional, Chang, Shao-Chun, additional, Abada, Paolo B, additional, Yang, Ling, additional, Schwartz, Jonathan D, additional, and Kudo, Masatoshi, additional

Published
2015
Full Text
View/download PDF

9. A randomized, multicenter study to determine the safety and efficacy of the immunoconjugate SGN-15 plus docetaxel for the treatment of non-small cell lung carcinoma

Author

Ross, Helen J., primary, Hart, Lowell L., additional, Swanson, Paul M., additional, Rarick, Mark U., additional, Figlin, Robert A., additional, Jacobs, Andrew D., additional, McCune, David E., additional, Rosenberg, Arthur H., additional, Baron, Ari D., additional, Grove, Laurie E., additional, Thorn, Michael D., additional, Miller, Dennis M., additional, Drachman, Jonathan G., additional, and Rudin, Charles M., additional

Published
2006
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results